Exploring the therapeutic potential of modern and ancestral phenylalanine/tyrosine ammonia-lyases as supplementary treatment of hereditary tyrosinemia

Phenylalanine/tyrosine ammonia-lyases (PAL/TALs) have been approved by the FDA for treatment of phenylketonuria and may harbour potential for complementary treatment of hereditary tyrosinemia Type I. Herein, we explore ancestral sequence reconstruction as an enzyme engineering tool to enhance the th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendrikse, Natalie M., Holmberg Larsson, Albin, Svensson Gelius, Stefan, Kuprin, Sergei, Nordling, Erik, Syrén, Per-Olof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987202/
https://www.ncbi.nlm.nih.gov/pubmed/31992763
http://dx.doi.org/10.1038/s41598-020-57913-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987202/
https://www.ncbi.nlm.nih.gov/pubmed/31992763
http://dx.doi.org/10.1038/s41598-020-57913-y

Ejemplares similares